Yeah, their CRO (?). But I don't see the rationale. There is nothing to lose with trying... Lernonlimab fulfills all the criteria for what makes a breakthrough IMO.

As trding wrote some time ago:

Quote:

---

Is leronlimab a breakthrough? Well the first possible mono approval, no developed resistance in 830 patients, combo trial with twice the efficacy of past approvals. No SAEs in 15 years. Better safety, better efficacy, lower toxicity, no resistance development. Longer half-life, with once a week dosing. Many of these patient developed resistance by skipping doses, they would allow them to be covered if they forget to take their pills a couple days.

---